Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials

OBJECTIVE: To estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses of data from two randomized, placebo‐controlled, Phase 3 trials, GWPCARE3 (NCT02224560) and GWPCARE4 (NCT02224690), of patients with Lennox–Gastaut...

Descripción completa

Detalles Bibliográficos
Autores principales: Privitera, Michael, Bhathal, Hari, Wong, Matthew, Cross, J. Helen, Wirrell, Elaine, Marsh, Eric D., Mazurkiewicz‐Beldzinska, Maria, Villanueva, Vicente, Checketts, Daniel, Knappertz, Volker, VanLandingham, Kevan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Full‐length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252057/
https://www.ncbi.nlm.nih.gov/pubmed/33797076
http://dx.doi.org/10.1111/epi.16878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252057/
https://www.ncbi.nlm.nih.gov/pubmed/33797076
http://dx.doi.org/10.1111/epi.16878

Ejemplares similares